Loading patent…
AssigneeInstitut Pasteur
InventorsAra Hovanessian, Jean Paul Briand, Sylviane Muller, Bernard Krust, Josette Svab, Elias Said
Estimating the term…
The present invention relates to peptides, referred to as CBD-1, CBD-2, CBM-1/TH-1, CBM-1/TH-2, CBM-2/TH-1, CBM-2/TH-2 and C-20 peptides, which are antigenic and elicit protective immune response against HIV infection. Compositions, pharmaceutical compositions and vaccines comprising these antigenic peptides are also encompassed by the present invention, as well as neutralizing antibodies which inhibit infection of primary CD4+ T lymphocytes by various HIV isolates. Methods for diagnosis of HIV are also disclosed.
A pharmaceutical composition comprising at least one peptide comprising at least one of the following peptide sequences:
5 The pharmaceutical composition according to any one of claims 1 to 4, wherein said at least one peptide is glycosylated, has introduced therein two cysteine residues to form a disulfide bridge or is phosphorylated.
A nucleic acid encoding the peptides of any one of sequences SEQ ID Nos. 1 to 9 and 11 to 18 or a sequence hybridizing under stringent conditions with the sequences thereof.
A kit to reduce to practice the method according to claim 26 comprising at least one peptide according to any one of claims 1 to 4, reagents necessary for the immunological reaction and reagents necessary for the detection of the immunological complex.
A purified peptide comprising at least one of SEQ ID Nos. 1 to 9 and 11 to 18 or of sequences having 90% to 99.9999% homology to SEQ ID Nos.1 to 9 and 11 to 18.
Dependencies are inferred from the claim text.